Most think that the CVD benefit of statins is entirely (or largely) explained by its LDL-c lowering effect while some argue that 'pleiotropic' effects (e.g. anti-inflammatory effects) are important.
There are some interesting differences between statins and PCSK9 inhibitors - for example, statins moderately reduce CRP unlike PCSK9 inhibition. Conversely, PCSK9 inhibitors reduce lipoprotein(a) whereas statins do not. As already noted in discussions below, FOURIER's CVD results (based on LDL-c reduction and trial duration) appear to match up very well with pooled CTT statin trial data despite these other differences.
Does this allow us to draw any insights regarding the importance (or perhaps lack of importance) of the effect of statins and PCSK9 inhibitors on inflammation and Lp(a)?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.